Leading the Way in Life Science Technologies

GEN Exclusives

More »

GEN News Highlights

More »
Feb 28, 2007

Peptisyntha Expands Production Capacity in Brussels.

  • Peptisyntha SA launched the expansion of its pilot-scale capacity for the production of cGMP bulk peptides based on solution phase technology at its production plant in Brussels. The expansion includes an additional pilot HPLC purification unit, an additional pilot freeze-dryer, and an additional pilot plant for the chemical synthesis of peptides. All the new units are scheduled to be fully operational in 2007.

    The current development follows the recent expansion of the solid phase peptide synthesis capacity implemented by Peptisyntha, Inc. in Torrance, CA, which came on stream in 2006. Peptisyntha SA and Peptisyntha Inc. are fully owned subsidiaries of Solvay.



Be sure to take the GEN Poll

Scientifically Studying Ecstasy

MDMA (commonly known as the empathogen “ecstasy”) is classified as a Schedule 1 drug, which is reserved for compounds with no accepted medical use and a high abuse potential. Two researchers from Stanford, however, call for a rigorous scientific exploration of MDMA's effects to identify precisely how the drug works, the data from which could be used to develop therapeutic compounds.

Do you agree that ecstasy should be studied for its potential therapeutic benefits?

More »